Kanvas Biosciences Secures Additional $12.5M in Funding
Summary
The company intends to use the funds to further develop its spatial biology platform and advance two novel therapeutics in its Immuno-oncology Program, KAN-001 and KAN-003 — KAN-001 to an Investigational New Drug (IND) filing in 2025. Led by CEO Matthew Cheng, Kanvas Biosciences is a spatial biology company building a microbiome drug screening, discovery and manufacturing platform to accelerate the development of live biotherapeutics. With an ability to spatially map the microbiome and profile host gene expression, and manufacture complex consortia containing hundreds of members that can restore microbiome health, the company is positioned to develop novel therapeutics that can improve the lives of all patients living with microbiome-associated diseases. KAN-001, the company’s lead drug candidate, is an LBP demonstrating significant potential to improve outcomes for cancer patients who have been resistant to immune checkpoint inhibitors (ICIs). Kanvas is collaborating with The University of Texas MD Anderson Cancer Center and its Platform for Innovative Microbiome and Translational Research (PRIME-TR) to conduct additional preclinical studies for KAN-001 to optimize the drug’s formulation and prepare it for an IND filing in 2025, preparatory to recruiting the first patients for a clinical trial the same year.
Funding
Review available funding amount, funding date, investors, and linked company information related to Kanvas Biosciences Secures Additional $12.5M in Funding in the interactive ISVWorld profile.